年間 6 号発行
ISSN 印刷: 1040-8401
ISSN オンライン: 2162-6472
Indexed in
Mode of Action of Botulinum Neurotoxins: Current Vaccination Strategies and Molecular Immune Recognition
要約
The action of a botulinum neurotoxin (BoNT) commences by binding at the nerve terminal via its H- (heavy) chain to a cell-surface receptor, which consists of a ganglioside and a cell-surface protein. Binding enables the L-chain, a Zn2+-dependent endopeptidase, to be internalized and act intracellularly, cleaving one or more SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins required for vesicle docking and fusion, which results in reduced neurotransmitter release. Sprouts emerge at motor-nerve terminals that reestablish synaptic contact and lead to restoration of exocytosis. As the terminals recover, sprouts retreat and synaptic function is fully re-established. Neutralizing antibodies (Abs) induced by vaccination can prevent the neuronal changes produced by BoNT. Until recently, vaccines against BoNT have been based on toxins inactivated by treatment with formaldehyde (toxoids) and contain either one (monovalent) or five (pentavalent) toxoids, but formalin-based toxoids have many undesirable side effects. Availability of the gene sequences of BoNT serotypes enabled design of recombinant subunit vaccines that have included the C-terminal domain of the H chain (HC, its subdomains (HC-N and HC-C), the L- (catalytic) chain, and the L-chain expressed with the translocation domain (LCHN). Of these, the HC displays the highest protective ability. Recent vaccines have used whole toxins inactivated by three key mutations at the enzyme active site, which have been found to be very effective in mice against the correlated toxin. Immune responses to BoNTs A and B epitopes are under the host’s MHC (major histocompatibility complex) control. Anti-BoNT/A blocking Abs bind at sites that coincide or overlap with those that bind synaptosomes and to BoNT/B at sites that overlap with synaptotagmin-II and ganglioside-binding sites. Therefore, locations occupied by blocking Abs preclude the respective toxin from binding to its receptor and thus from binding to cell surface. Information on BoNT epitopes for blocking Abs, sites for binding to cell surface receptors, and T-cell epitopes that provide help to B cells making blocking Abs afford a prospect for rational design of stable synthetic vaccines. These constructs should be clinically useful for epitope-selective modulation of Ab responses to restore effective BoNT treatment in immunoresistant patients.
-
Eichhorn Tolga, Dolimbek Behzod Z., Deeg Katharina, Efferth Thomas, Atassi M. Zouhair, Inhibition in vivo of the activity of botulinum neurotoxin A by small molecules selected by virtual screening, Toxicon, 60, 6, 2012. Crossref
-
Karalewitz Andrew P-A, Barbieri Joseph T, Vaccines against botulism, Current Opinion in Microbiology, 15, 3, 2012. Crossref
-
George Katherine S., Kiani Hamid, Witherow Helen, Effectiveness of botulinum toxin B in the treatment of drooling, British Journal of Oral and Maxillofacial Surgery, 51, 8, 2013. Crossref
-
Henkel James S., Tepp William H., Przedpelski Amanda, Fritz Robert B., Johnson Eric A., Barbieri Joseph T., Subunit vaccine efficacy against Botulinum neurotoxin subtypes, Vaccine, 29, 44, 2011. Crossref
-
Atassi M. Zouhair, Taruishi Midori, Naqvi Masooma, Steward Lance E., Aoki K. Roger, Synaptotagmin II and Gangliosides Bind Independently with Botulinum Neurotoxin B but Each Restrains the Other, The Protein Journal, 33, 3, 2014. Crossref
-
Atassi M. Zouhair, Oshima Minako, Dolimbek Behzod Z., Aoki K. Roger, Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains, Immunobiology, 217, 1, 2012. Crossref
-
Yu YunZhou, Shi DanYang, Liu Si, Gong Zheng-Wei, Wang Shuang, Sun ZhiWei, Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system, Human Vaccines & Immunotherapeutics, 11, 2, 2015. Crossref
-
Lim Erle C. H., Seet Raymond C. S., Use of botulinum toxin in the neurology clinic, Nature Reviews Neurology, 6, 11, 2010. Crossref
-
Moreira G.M.S.G., Cunha C.E.P., Salvarani F.M., Gonçalves L.A., Pires P.S., Conceição F.R., Lobato F.C.F., Production of recombinant botulism antigens: A review of expression systems, Anaerobe, 28, 2014. Crossref
-
Atassi M. Zouhair, Dolimbek Behzod Z., Steward Lance E., Aoki K. Roger, Inhibition of Botulinum Neurotoxin A Toxic Action In Vivo by Synthetic Synaptosome- and Blocking Antibody-Binding Regions, The Protein Journal, 29, 5, 2010. Crossref
-
Lu Alex Y., Yeung Jacky T., Gerrard Jason L., Michaelides Elias M., Sekula Raymond F., Bulsara Ketan R., Hemifacial Spasm and Neurovascular Compression, The Scientific World Journal, 2014, 2014. Crossref
-
Atassi M. Zouhair, Dolimbek Behzod Z., Steward Lance E., Aoki K. Roger, Antibodies against a synthetic peptide designed to mimic a surface area of the H chain of botulinum neurotoxin A, Immunology Letters, 142, 1-2, 2012. Crossref
-
Tang Christopher G., Novakovic Daniel, Mor Niv, Blitzer Andrew, Onabotulinum toxin A dosage trends over time for adductor spasmodic dysphonia: A 15-year experience, The Laryngoscope, 126, 3, 2016. Crossref
-
Dolimbek Behzod Z., Aoki K. Roger, Atassi M. Zouhair, Reduction of antibody response against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol–peptide conjugates, Immunology Letters, 137, 1-2, 2011. Crossref
-
Lim Erle C.H., Quek Amy M.L., Seet Raymond C.S., Accurate targeting of botulinum toxin injections: How to and why, Parkinsonism & Related Disorders, 17, 2011. Crossref
-
Liu Bo, Shi DanYang, Chang ShaoHong, Gong Xin, Yu YunZhou, Sun ZhiWei, Wu Jun, Characterization and immunological activity of different forms of recombinant secreted Hc of botulinum neurotoxin serotype B products expressed in yeast, Scientific Reports, 5, 1, 2015. Crossref
-
Vijayalakshmi Ayyar B., Tajhya Rajeev B., Beeton Christine, Zouhair Atassi M., Antigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin, Scientific Reports, 5, 1, 2015. Crossref
-
Smith Garry R., Caglič Dejan, Čapek Petr, Zhang Yan, Godbole Sujata, Reitz Allen B., Dickerson Tobin J., Reexamining hydroxamate inhibitors of botulinum neurotoxin serotype A: Extending towards the β-exosite, Bioorganic & Medicinal Chemistry Letters, 22, 11, 2012. Crossref
-
Atassi M.Z., Molecular basis of immunogenicity to botulinum neurotoxins and uses of the defined antigenic regions, Toxicon, 107, 2015. Crossref
-
Kroken Abby R., Karalewitz Andrew P.-A., Fu Zhuji, Baldwin Michael R., Kim Jung-Ja P., Barbieri Joseph T., Unique ganglioside binding by botulinum neurotoxins C and D-SA, FEBS Journal, 278, 23, 2011. Crossref
-
Ruwona Tinashe B., Xu Haiyue, Li Junwei, Diaz-Arévalo Diana, Kumar Amit, Zeng Mingtao, Cui Zhengrong, Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles, Human Vaccines & Immunotherapeutics, 12, 5, 2016. Crossref
-
Ayyar B. Vijayalakshmi, Atassi M. Zouhair, Effects of membrane properties on the binding activities of the H N and H C heavy-chain domains of botulinum neurotoxin A, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1864, 12, 2016. Crossref
-
Moreira Clóvis, da Cunha Carlos Eduardo Pouey, Moreira Gustavo Marçal Schmidt Garcia, Mendonça Marcelo, Salvarani Felipe Masiero, Moreira Ângela Nunes, Conceição Fabricio Rochedo, Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D, Anaerobe, 40, 2016. Crossref
-
Oliveira Júnior Carlos Augusto de, Silva Rodrigo Otávio Silveira, Olinda Roberio Gomes, Lobato Francisco Carlos Faria, Botulism in non-ruminants in Brazil, Ciência Rural, 46, 12, 2016. Crossref
-
Silva Rodrigo Otávio Silveira, Oliveira Junior Carlos Augusto, Gonçalves Luciana Aramuni, Lobato Francisco Carlos Faria, Botulism in ruminants in Brazil, Ciência Rural, 46, 8, 2016. Crossref
-
Zheng Feixia, Ye Xiuyun, Shi Xulai, Poonit Neha Devi, Lin Zhongdong, Management of Refractory Orofacial Dyskinesia Caused by Anti-N-methyl-d-aspartate Receptor Encephalitis Using Botulinum Toxin, Frontiers in Neurology, 9, 2018. Crossref
-
Marchese M.R., D'Alatri L., Bentivoglio A.R., Paludetti G., OnabotulinumtoxinA for adductor spasmodic dysphonia (ADSD): Functional results and the role of dosage, Toxicon, 155, 2018. Crossref
-
Adler Michael, Gul Nizamettin, Eitzen Edward, Oyler George, Molles Brian, Prevention and Treatment of Botulism, in Molecular Aspects of Botulinum Neurotoxin, 2014. Crossref
-
Dolimbek Behzod Z., Steward Lance E., Aoki K. Roger, Atassi M. Zouhair, Location of the Synaptosome-Binding Regions on Botulinum Neurotoxin B, Biochemistry, 51, 1, 2012. Crossref
-
O'Flaherty Sarah, Klaenhammer Todd R., Dudley E. G., Multivalent Chromosomal Expression of the Clostridium botulinum Serotype A Neurotoxin Heavy-Chain Antigen and the Bacillus anthracis Protective Antigen in Lactobacillus acidophilus, Applied and Environmental Microbiology, 82, 20, 2016. Crossref
-
Li Zhen, Lu Jiansheng, Tan Xiao, Wang Rong, Xu Qing, Yu Yunzhou, Yang Zhixin, Functional EL-HN Fragment as a Potent Candidate Vaccine for the Prevention of Botulinum Neurotoxin Serotype E, Toxins, 14, 2, 2022. Crossref